Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07258173
Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita (EMOTI)
Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita: a Phase II, Randomized, Double Blind, Controlled Trial
Sponsor: Bayer
Conditions
Trichuris Trichuris Infection
Interventions
Albendazole 400 mg Emodepside
Updated 1 time since 2026 Last updated: Nov 20, 2025 Started: Jan 15, 2026 Primary completion: May 15, 2026 Completion: May 15, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Trichuris and Trichuris Infection and is currently actively recruiting participants. Bayer leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Bayer
- Centre Suisse de Recherches Scientifiques en Cote d'Ivoire
- Jennifer Keiser
- Université Félix Houphouët-Boigny
Data source: Swiss Tropical & Public Health Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.